德国菌菇玫克微朵:靶向药和免疫治疗,谁能成为肺癌患者耐药后的“大招”?( 二 )


[5]Y.Fan,etal.SafetyandEfficacyofDabrafenibPlusTrametinibinChinesePatientswithBRAFV600E-MutationPositiveMetastaticNSCLC.2022WCLC.EP08.02-052.
[6]DrilonA,etal.Durabilityofefficacyandsafetywithselpercatinibinpatients(pts)withRETfusion+non-smallcelllungcancer(NSCLC).2022ELCC.27P.
[7]LuS,etal.EfficacyandsafetyofselpercatinibinChinesepatientswithadvancedRETfusion-positivenon-small-celllungcancer:aphaseIIclinicaltrial(LIBRETTO-321).TherAdvMedOncol.2022;14:17588359221105020.返回搜狐 , 查看更多
责任编辑: